HeartGenetics Genetics and Biotechnology S.A.

HeartGenetics, Genetics and Biotechnology S.A. is a Portuguese genetics and computational biology company headquartered in Cantanhede, Portugal. Founded in 2013, the company describes itself as a digital health company that adds intelligence to genetic data, combining a licensed medical genetics laboratory with proprietary software tools. Its core technology platform, HEARTDECODE, is designed for intelligent reporting of genetic results, and the company states that it is a licensed medical genetics laboratory (licence no. 17207/2019) and an ISO 9001:2015 certified company. The company operates at the intersection of genetics, bioinformatics and preventive medicine. Its R&D team, drawing on more than 15 years of research in cardiovascular and bioinformatics fields, has developed genetic tests and reports intended to support personalised therapeutic and lifestyle plans. HeartGenetics uses a DNA-based microchip platform optimised for genetic testing using the iPLEX MassArray system, together with scalable algorithms for processing and integrating heterogeneous data such as genetic, clinical, pharmacogenetic, medical guideline, and health and wellness information. HeartGenetics organises its commercial offering into three main areas. In preventive genetics and wellness, it markets MyNutriGenes, MyWellnessGenes, MyVitDGenes and MyFitnessGenes, which are positioned to improve health and wellness through nutrition, vitamin D intake, fitness and wellness. In cardiovascular genetics, it offers TromboGene, focused on hereditary thrombophilias and the identification of genetic markers associated with increased risk of thromboembolic events. In pharmacogenomics, it provides MyPharmaGenes, MyPharmaGenes Brain and MyCannabisGenes, which investigate the correlation between an individual's genetic profile and their response to drugs using genetic markers to tailor treatment. The company positions itself as a partner for both patients and specialists, guiding users through its genetic services and supporting clinical evaluation. It emphasises a multidisciplinary team of PhDs and specialists in genetics, bioinformatics and molecular biology, and claims that its genetic tests have 99% accuracy. HeartGenetics also highlights value-based healthcare and personalised medicine as strategic themes, and its materials reference EU-funded projects, awards and recognitions, and an advisory board. As a private company, HeartGenetics is not listed on a stock exchange. Its headquarters in Cantanhede, in the central region of Portugal, place it within the country's growing life sciences and biotechnology ecosystem. The company's public communications focus on preventive, participative and predictive heart medicine, and on expanding the use of genetic information to improve health and wellness.

HeartGenetics, Genetics and Biotechnology S.A. was founded in 2013 in Portugal. The company was established with the aim of playing a key role in applied genetic knowledge and genetic testing, focusing on the fields of pharmacogenetics, cardiovascular genetics and wellbeing. Its formation built on more than 15 years of research in cardiovascular and bioinformatics fields, which provided the scientific foundation for its R&D team to develop new genetic tests and reports. From its base in Cantanhede, Portugal, HeartGenetics developed a methodology combining a DNA-based microchip platform optimised for genetic testing using the iPLEX MassArray system with a set of efficient, scalable and sophisticated algorithms for processing and integrating heterogeneous data. This data ranges from genetic, clinical, pharmacogenetic and medical guideline information to health and wellness data. The company describes itself as active in genetics and computational biology, and it developed the HEARTDECODE system for intelligent reporting as the core of its software tools. Over time, HeartGenetics expanded its commercial portfolio across three main areas. In preventive genetics and wellness, it introduced MyNutriGenes, MyWellnessGenes, MyVitDGenes and MyFitnessGenes, aimed at improving health and wellness through nutrition, vitamin D intake, fitness and wellness. In cardiovascular genetics, it developed TromboGene for the study of hereditary thrombophilias and the identification of genetic markers associated with increased risk of thromboembolic events. In pharmacogenomics, it launched MyPharmaGenes, MyPharmaGenes Brain and MyCannabisGenes, which investigate the correlation between an individual's genetic profile and their response to drugs. The company has emphasised quality and regulatory compliance, stating that it is a licensed medical genetics laboratory (licence no. 17207/2019) and an ISO 9001:2015 certified company. It has also highlighted an award-winning methodology and claims 99% accuracy for its genetic tests. HeartGenetics presents itself as a partner for both patients and specialists, guiding users through its genetic services, and it references EU-funded projects, awards and recognitions, and an advisory board in its public materials. As of the available evidence, HeartGenetics remains an active private company headquartered in Cantanhede, Portugal, dedicated to keeping people healthy through the use of genetic information and to supporting value-based healthcare in wellness, cardiovascular and pharmacogenetics.

• 2019

  Company holds medical genetics laboratory licence no. 17207/2019.

• 2013

  HeartGenetics, Genetics and Biotechnology S.A. is founded in Portugal.

Digital health and genetics company adding intelligence to genetic data for preventive, personalised medicine in wellness, cardiovascular and pharmacogenomics.

• MyNutriGenes

  Preventive genetics test for nutrition-related genetic insights.

• MyWellnessGenes

  Wellness genetic test to support personalised lifestyle plans.

• MyVitDGenes

  Genetic test related to vitamin D intake and metabolism.

• MyFitnessGenes

  Genetic test for fitness and wellness personalisation.

• TromboGene

  Cardiovascular genetics test for hereditary thrombophilias and thromboembolic risk markers.

• MyPharmaGenes

  Pharmacogenomics test correlating genetic profile with drug response.

• MyPharmaGenes Brain

  Pharmacogenomics test focused on brain-related treatments.

• MyCannabisGenes

  Pharmacogenomics test related to cannabis response.

• HEARTDECODE

  Proprietary intelligent reporting system for genetic data.

1. 1HeartGenetics - Genetics and Biotechnology Homepageheartgenetics.com
2. 2Why us | HeartGenetics, Genetics & Biotechnologyheartgenetics.com
3. 3HeartGenetics Genetics and Biotechnology (Portugal) - Wikidatawikidata.org